Hprt-CAG-LSL-ROCK2:ER
| Status | Available to order |
| EMMA ID | EM:11383 |
| International strain name | Hprt-CAG-LSL-ROCK2:ER |
| Alternative name | Hprt-CAG-LSL-ROCK2:ER |
| Strain type | Targeted Mutant Strains : Other targeted |
| Allele/Transgene symbol | Unknown at present |
| Gene/Transgene symbol | Hprt1 |
Information from provider
| Provider | Michael Olson |
| Provider affiliation | Cancer Research UK Beatson Institute |
| Genetic information | Hprt-CAG-LSL-ROCK2:ER |
| Phenotypic information | Homozygous:The Hprt-CAG-LSL-ROCK2:ER targeted transgene enables CRE-inducible expression of a conditionally-active fusion between the ROCK2 kinase domain and the hormone-binding domain of a mutated estrogen receptor (ROCK2:ER), which then requires administration of estrogen analogues such as tamoxifen or 4-hydroxytamoxifen to elicit kinase activity. Given the X-chromosome location, homozygous females have one active copy due to X-chromosome inactivation, while males cannot be homozygous.Heterozygous:Hprt-CAG-LSL-ROCK2:ER enables CRE-inducible expression of a conditionally-active fusion between the ROCK2 kinase domain and the hormone-binding domain of a mutated estrogen receptor (ROCK2:ER), which then requires administration of estrogen analogues such as tamoxifen or 4-hydroxytamoxifen to elicit kinase activity. Males can only be hemizygous, heterozygous females may display mosaic patterns of expression due to X-chromosome inactivation. |
| References | None available |
| Homozygous fertile | yes |
| Homozygous viable | yes |
| Homozygous matings required | no |
| Immunocompromised | no |
Information from EMMA
| Archiving centre | Mary Lyon Centre at MRC Harwell, Oxford, United Kingdom |